Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been
substantially improved with the emergence of novel therapeutic agents, such as proteasome …

The myeloma surface proteome (surfaceome) determines tumor interaction with the
microenvironment and serves as an emerging arena for therapeutic development. Here, we …

Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …

T cells expressing chimeric antigen receptors (CARs) have shown remarkable therapeutic
activity against different types of cancer. However, the wider use of CAR T cells has been …

The signaling lymphocytic activation molecule (SLAM) family receptors were discovered in
immune cells for the first time. The SLAM-family receptors are a significant player in …

Two mechanisms are involved in the immune escape of cancer cells: the immunoediting of
tumor cells and the suppression of the immune system. Both processes have been revealed …

Despite recent therapeutic advances, the prognosis of multiple myeloma (MM) patients
remains poor. Thus, new strategies to improve outcomes are imperative. Chimeric antigen …

Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment
landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients …

The treatment of multiple myeloma (MM) has entered into a new era of immunotherapy.
Novel immunotherapies will significantly improve patient outcome via simultaneously …